WHO Sounds Concern Over Severe Scarcity of Obesity Injections

Fewer than a tenth of patients that would benefit from obesity jabs like Wegovy have access to them, states the WHO as it releases its initial guidance on the therapies.

Considering more than one billion people worldwide currently classified as obese, it is advocating for more widespread and fairer access to these injectable treatments.

According to estimates, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.

"Our new guidelines affirms that obesity is a long-term condition that can be addressed with holistic and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and supply-chain constraints are significant barriers to broad availability to the injections that can help people shift substantial body mass, notes the agency.

GLP-1 Therapy Supply Crisis

Despite the present most optimistic outlook, the supply of such drugs might only reach around 100 million people – fewer than 10% of those who need them, as stated by the health organization.

The advice calls on countries and companies to widen access, by strategies such as voluntary licensing.

Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.

How Weight-Loss Jabs Operate

GLP-1 drugs replicate a body's own hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so individuals eat less.

People usually begin shedding pounds within a few weeks of commencing the regular doses.

Studies indicates users may put most of the weight back on a year later of discontinuing the drug, because their usual appetite return.

To be above a healthy weight raises your chance for contracting medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity impacts people in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.